Loncastuximab Tesirine + Rituximab for PTLD

(PLUTO Trial)

This trial tests two drugs, loncastuximab tesirine and rituximab, to determine the best dose and assess their effectiveness for people with post-transplant lymphoproliferative disorders (PTLD), a condition that can develop after an organ transplant. In the first part of the trial, researchers aim to identify the optimal dosage. The second part evaluates the effectiveness of these drugs in treating PTLD. Individuals with PTLD following a solid organ transplant, confirmed through a medical diagnosis, might be eligible for this study. As a Phase 1/Phase 2 trial, the research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

The trial requires a washout period (time without taking certain medications) for any prohibited medications, lasting at least five half-lives of the medication or as clinically indicated. It's best to discuss your current medications with the trial team to see if any are prohibited.

Research shows that the combination of loncastuximab tesirine and rituximab is generally safe. Studies have found that most patients tolerate the treatment well, with side effects that are usually manageable. In one study involving patients with relapsed or hard-to-treat follicular lymphoma, this treatment proved both effective and safe, with most participants responding positively. Additionally, other studies have confirmed that loncastuximab tesirine, also known as ZYNLONTA®, is generally well-tolerated. While side effects can occur, they are often mild and treatable. Overall, the evidence suggests these treatments are safe for most people.¹²³⁴⁵

Researchers are excited about Loncastuximab Tesirine combined with Rituximab for treating post-transplant lymphoproliferative disorder (PTLD) because it introduces a novel approach. Unlike standard treatments like R-CHOP or monotherapy with Rituximab, Loncastuximab Tesirine is an antibody-drug conjugate that delivers a potent cytotoxic agent directly to the cancer cells, sparing more of the healthy cells. This targeted mechanism could lead to more effective outcomes with potentially fewer side effects. Additionally, the combination with Rituximab enhances the treatment's ability to specifically target and destroy B-cell malignancies, which could significantly improve the prognosis for patients with PTLD.

This trial will evaluate the combination of two drugs, loncastuximab tesirine and rituximab, for treating post-transplant lymphoproliferative disorders (PTLD). Studies have shown that rituximab alone may not always be effective, but adding loncastuximab tesirine, which specifically targets cancer cells, can lead to better outcomes. For example, some studies have demonstrated that this combination controls tumors more effectively. Participants in this trial will receive different dose levels of this combination, and researchers will assess their responses to determine the treatment's effectiveness. This approach has shown promise in past trials, suggesting it could be a strong option for treating PTLD.¹²⁴⁵⁶